MedTrace Logo

Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major

NCT03171831 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-05-31

No results posted yet for this study

Summary

The purpose of the study is to assess the safety and efficacy of haploidentical hematopoietic stem cell transplantation for patients with thalassemia major.

Conditions

  • Thalassemia Major

Interventions

DRUG

Busulfan

Busulfan（4 mg/kg/day,4 days）

DRUG

Cyclophosphamide

Cyclophosphamide（50 mg/kg/day,4 days）

DRUG

Fludarabine

Fludarabine（50 mg/m2/day,3 days）

DRUG

Mycophenolate mofetil

Mycophenolate mofetil（0.25g/day）

DRUG

Tacrolimus

Tacrolimus（0.03mg/kg/day）

DRUG

Methotrexate

Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）

DRUG

Thymoglobulin

Thymoglobulin（2.5 mg/kg/day,4 days）

DRUG

Basiliximab

Basiliximab（10mg on day 0 and +4）

Sponsors & Collaborators

  • First Affiliated Hospital of Guangxi Medical University

    lead OTHER

Principal Investigators

  • Yongrong Lai, MD · First Affiliated Hospital of Guangxi Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-01
Primary Completion
2021-12-31
Completion
2022-04-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03171831 on ClinicalTrials.gov